January 26, 2025 - 15:58

It looks like First National Financial Corporation is about to go ex-dividend in the next four days. The company has announced a dividend payment of CA$0.208334, which is scheduled to be distributed shortly. This upcoming dividend is part of First National's ongoing commitment to return value to its shareholders.
Investors who hold shares before the ex-dividend date will be eligible to receive this payment, which reflects the company's solid financial performance and stability in the market. Dividends are an important aspect for many investors, as they provide a steady income stream and can indicate the company's profitability and growth potential.
As the ex-dividend date approaches, shareholders are advised to keep an eye on their holdings to ensure they do not miss out on this upcoming payout. With a history of consistent dividend payments, First National Financial Corporation continues to attract attention from both current and prospective investors looking for reliable income-generating opportunities.
May 14, 2026 - 00:55
Aeluma Announces Third Quarter Fiscal 2026 Financial ResultsAeluma, Inc., a company specializing in compound semiconductor technologies, has released its financial results for the third quarter of fiscal year 2026. The report comes alongside several major...
May 13, 2026 - 11:31
MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives ContinueHealthcare distributor McKesson reported first-quarter earnings that missed revenue expectations, though the company continued to push ahead with margin-focused initiatives. For the quarter ending...
May 12, 2026 - 23:07
Prudential Financial Declares Quarterly Dividend on Common StockNEWARK, N.J., May 12, 2026 -- Prudential Financial, Inc. has declared a quarterly dividend of $1.40 per share on its common stock. The payment is scheduled for June 11, 2026, and will go to...
May 12, 2026 - 03:06
Cellectis Reports First Quarter 2026 Financial ResultsCellectis has announced its financial results for the first quarter of 2026, alongside updates on its clinical pipeline and preclinical research programs. The company is advancing its pivotal...